Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACE trial: Neoadjuvant radiochemotherapy vs chemotherapy for locally advanced GEJ adenocarcinoma
2024-516271-32-00Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, docetaxel, oxaliplatin and folinic acid in gastroesophageal junction adenocarcinoma (2 arms), sponsored by Heidelberg University. Primary endpoint: Progression-free survival. Started Nov 2024; status: completed.
02
Drugs
fluorouracildocetaxeloxaliplatinfolinic acid
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-516271-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516271-32-00.